Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2026)

Talphera (TLPH) posted Net Income towards Common Stockholders of -$3.8 million for Q2 2026, up 0.71% on a QoQ basis from -$3.8 million in Q1 2026, and down 3.93% year-over-year from -$3.9 million in Q2 2025.

Analysis

Talphera (TLPH) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends

Talphera has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$3.8 million in Q2 2026.

  • On a quarterly basis, Net Income towards Common Stockholders fell 3.93% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 10.97% from the prior year.
  • Net Income towards Common Stockholders was -$3.8 million for Q2 2026 at Talphera, up from -$3.8 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $66.8 million in Q2 2022, with the low at -$13.4 million in Q1 2022.
  • Average Net Income towards Common Stockholders over 5 years is $251277.8, with a median of -$3.7 million recorded in 2025.
  • The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders surged 778.14% in 2022, then tumbled 148.89% in 2024.
  • Over 5 years, Net Income towards Common Stockholders stood at -$5.2 million in 2022, then increased by 13.07% to -$4.5 million in 2023, then jumped by 35.95% to -$2.9 million in 2024, then fell by 12.34% to -$3.2 million in 2025, then declined by 15.45% to -$3.8 million in 2026.
  • The last three Net Income towards Common Stockholders figures came in at -$3.8 million (Q2 2026), -$3.8 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 472.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -290.61 Mn
10 Talphera 92.90 Mn 92.90 Mn - -3.75 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -3.75 Mn
Mar 31, 2026 -3.78 Mn
Dec 31, 2025 -3.25 Mn
Sep 30, 2025 -3.34 Mn
Jun 30, 2025 -3.61 Mn
Mar 31, 2025 -2.77 Mn
Dec 31, 2024 -2.89 Mn
Sep 30, 2024 -3.35 Mn
Jun 30, 2024 -3.83 Mn
Mar 31, 2024 -4.02 Mn
Dec 31, 2023 -4.52 Mn
Sep 30, 2023 -1.42 Mn
Jun 30, 2023 -4.43 Mn
Mar 31, 2023 8.22 Mn
Dec 31, 2022 -5.20 Mn
Sep 30, 2022 -6.94 Mn
Jun 30, 2022 66.80 Mn
Mar 31, 2022 -13.41 Mn
Dec 31, 2021 -7.92 Mn
Sep 30, 2021 -8.38 Mn